Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CTRC | Q99895 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38750 | 1.00 | NPC1 (0.52) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL42618 | 0.89 | SMN1; SMN2 (0.47) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL42619 | 0.89 | SMN1; SMN2 (0.47) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL38663 | 0.86 | PPARA (0.51) | NPC1MAPTRAB9APPARA | |
| SCHEMBL43048 | 0.86 | PPARA (0.51) | NPC1MAPTRAB9APPARA | |
| SCHEMBL47175 | 0.86 | MAPT (0.62) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL12966546 | 0.85 | PPARA (0.57) | NPC1MAPTRAB9APPARA | |
| SCHEMBL14506325 | 0.85 | PPARA (0.47) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5444450 | 0.85 | PPARA (0.47) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5444445 | 0.85 | PPARA (0.47) | NPC1MAPTRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426390-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN THERAPEUTICS GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-8034797-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN PHARMA GMBH (CH) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | NPC1 264/4885MAPT 1925/4885RAB9A 409/4885 |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | NPC1 264/4885MAPT 1925/4885RAB9A 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.